PMID- 29163673
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220408
IS  - 1758-5996 (Print)
IS  - 1758-5996 (Electronic)
IS  - 1758-5996 (Linking)
VI  - 9
DP  - 2017
TI  - Effects of pioglitazone therapy on blood parameters, weight and BMI: a 
      meta-analysis.
PG  - 90
LID - 10.1186/s13098-017-0290-5 [doi]
LID - 90
AB  - BACKGROUND: Type 2 diabetes mellitus (T2DM) is one of the most common diseases 
      worldwide and insulin insufficiency and insulin resistance are two main metabolic 
      issues connected with it. The dyslipidemia associated with insulin resistance and 
      T2DM is characterized by higher triglycerides (TGs), higher very-low-density 
      lipoprotein cholesterol and lower apo A1. Pioglitazone, a member of the 
      thiazolidinedione class, with a proven antihyperglycemic effect, is known to 
      positively influence insulin sensitivity and beta-cell function and to have the 
      potential to alter the lipid profile. METHODS: The aim of our meta-analysis is to 
      summarize and determine the influence of pioglitazone on the glycemic profile and 
      lipoprotein metabolism as well as on weight and BMI in order to highlight the 
      benefit of pioglitazone therapy in patients with T2DM. A comprehensive literature 
      search was conducted through the electronic databases PubMed, MEDLINE, Scopus, 
      PsyInfo, eLIBRARY.ru (from 2000 until February 2016) to identify studies that 
      investigate the effect of pioglitazone on the glycemic and lipid profile and on 
      the weight and BMI. We chose the random-effects method as the primary analysis. 
      Forest plots depict estimated results from the studies included in the analysis 
      and funnel plots are used to evaluate publication bias. Sensitivity analyses were 
      performed in order to evaluate the degree of influence of the consequent 
      elimination of each individual study on the final result. RESULTS: Of the 1536 
      identified sources only 15 randomised trials were included in the meta-analysis. 
      Pioglitazone treatment was associated with improvement in the glycemic profile. 
      It reduced FPG levels by a mean of 1.1-2 mmol/l and HbA1c by a mean of 0.9-1.3%. 
      Our results reaffirmed the hypothesis that pioglitazone has a positive influence 
      on the lipid profile of T2DM patients with increase in TC and HDL, no significant 
      changes in LDL and notable decrease in TGs. Results also showed that pioglitazone 
      therapy led to increase in both weight and BMI (WMD 1.755, 95% CI 0.674 to 2.837 
      and 1.145, 95% CI 0.389 to 1.901 respectively). CONCLUSION: Our results prove 
      that the PPAR gamma agonist pioglitazone has the potential to be beneficial to 
      patients with T2DM.
FAU - Filipova, Elena
AU  - Filipova E
AUID- ORCID: 0000-0002-5786-0832
AD  - Science Department, Tchaikapharma High Quality Medicines Inc., 1 G.M. Dimitrov 
      Blvd, 1172 Sofia, Bulgaria.
FAU - Uzunova, Katya
AU  - Uzunova K
AD  - Science Department, Tchaikapharma High Quality Medicines Inc., 1 G.M. Dimitrov 
      Blvd, 1172 Sofia, Bulgaria.
FAU - Kalinov, Krassimir
AU  - Kalinov K
AD  - Department of Informatics, New Bulgarian University, 21 Montevideo Str, 1618 
      Sofia, Bulgaria. ISNI: 0000 0001 0740 5199. GRID: grid.5507.7
FAU - Vekov, Toni
AU  - Vekov T
AD  - Faculty of Pharmacy, Medical University, Pleven, Bulgaria. ISNI: 0000 0000 9212 
      7703. GRID: grid.411711.3
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171114
PL  - England
TA  - Diabetol Metab Syndr
JT  - Diabetology & metabolic syndrome
JID - 101488958
PMC - PMC5686837
OTO - NOTNLM
OT  - BMI
OT  - Glycemic profile
OT  - Lipid profile
OT  - Pioglitazone
OT  - Weight
EDAT- 2017/11/23 06:00
MHDA- 2017/11/23 06:01
PMCR- 2017/11/14
CRDT- 2017/11/23 06:00
PHST- 2017/07/21 00:00 [received]
PHST- 2017/11/02 00:00 [accepted]
PHST- 2017/11/23 06:00 [entrez]
PHST- 2017/11/23 06:00 [pubmed]
PHST- 2017/11/23 06:01 [medline]
PHST- 2017/11/14 00:00 [pmc-release]
AID - 290 [pii]
AID - 10.1186/s13098-017-0290-5 [doi]
PST - epublish
SO  - Diabetol Metab Syndr. 2017 Nov 14;9:90. doi: 10.1186/s13098-017-0290-5. 
      eCollection 2017.